SELLAS Life Sciences Group (SELLAS Life Sciences Group) Short-Term Debt & Capital Lease Obligation : $0.45 Mil (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. SELLAS Life Sciences Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.45 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. SELLAS Life Sciences Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.46 Mil.

SELLAS Life Sciences Group Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for SELLAS Life Sciences Group's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Short-Term Debt & Capital Lease Obligation Chart

SELLAS Life Sciences Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.22

0.17

0.20

0.37

0.45

SELLAS Life Sciences Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															0.37	0.43	0.45	0.47	0.45

SELLAS Life Sciences Group Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

SELLAS Life Sciences Group Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

SELLAS Life Sciences Group (SELLAS Life Sciences Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (NAS:SLS) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

RXK3:Germany

Address

7 Times Square, Suite 2503, New York, NY, USA, 10036

Website

https://www.sellaslifesciences.com

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Executives

Angelos M. Stergiou	director, officer: President and CEO	C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, SUITE 380, SAN RAMON CA 94583
Barbara A Wood	officer: EVP, Gen. Counsel, Corp. Sec.	58 S SERVICE RD, MELVILLE NY 11747
John Thomas Burns	officer: VP, Finance & Corp Controller	16760 SW UPPER BOONES FERRY RD, SUITE 101, PORTLAND X1 97224
Katherine Bach Kalin	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Robert Francomano	officer: Chief Commercial Officer	C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 11TH FLOOR, NEW YORK NY 10022
Nicholas J. Sarlis	officer: Chief Medical Officer and SVP	C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, STE. 380, SAN RAMON CA 94583
Stephen F Ghiglieri	director	C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Jane Wasman	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David A Scheinberg	director	325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
John Varian	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely Ii Fund`	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely I Fund	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Equilibria Capital Management Ltd	10 percent owner	O'HARA HOUSE, ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Ii Sac Fund Ltd-eqc Biotech Sely Iii Fund	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08